Home > Rheumatology > ACR 2020 > What Is Hot in Lupus Nephritis? > Lupus nephritis biomarkers: moving toward an omic-driven approach

Lupus nephritis biomarkers: moving toward an omic-driven approach

Presented By
Prof. Chaim Putterman, Albert Einstein College of Medicine, USA
ACR 2020
Lupus nephritis affects up to 60% of patients with systemic lupus erythematosus. Current biomarkers are not reliable, but a novel “omic”-driven approach might be a more successful way for risk prediction. “In lupus nephritis, we believe that ‘time is kidney’,” said Prof. Chaim Putterman (Albert Einstein College of Medicine, USA) [1]. Lupus nephritis (LN) is a major risk factor for morbidity and mortality in systemic lupus erythematosus (SLE). According to a study, delay between the detection of the onset of renal disease and renal biopsy was a significant predictor for subsequent renal insufficiency and death due to lupus renal involvement. Therefore, biomarkers are of particular importance in LN, because early diagnosis and treatment make a difference. Prompt therapy with prednisone and immunosuppressive agents in LN has a beneficial effect on long-term prognosis. Unfortunately, increasing double-stranded (ds)DNA antibodies, presently used as bioma...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on